Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Quercus Velutina Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of oak-pollen-induced allergic rhinitis and conjunctivitis. It belongs to the class of allergenic extracts used in subcutaneous immunotherapy (SCIT).
Name
Quercus Velutina Pollen
Raw Name
QUERCUS VELUTINA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
12
Variant Count
13
Last Verified
February 17, 2026
About Quercus Velutina Pollen
Quercus Velutina Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of oak-pollen-induced allergic rhinitis and conjunctivitis. It belongs to the class of allergenic extracts used in subcutaneous immunotherapy (SCIT).
Detailed information about Quercus Velutina Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Quercus Velutina Pollen.
Quercus Velutina Pollen, commonly known as Black Oak pollen, is a biological substance used in the field of allergy and immunology. It belongs to a class of drugs known as Non-Standardized Pollen Allergenic Extracts. These extracts are derived from the pollen of the Quercus velutina tree, a member of the Fagaceae family native to eastern and central North America. In clinical practice, this extract is utilized for two primary purposes: the diagnostic identification of hypersensitivity (allergy) through skin testing and the long-term treatment of allergic disease through immunotherapy, often referred to as 'allergy shots.'
As a non-standardized extract, the potency of Quercus Velutina Pollen is typically expressed in terms of weight/volume (w/v) or Protein Nitrogen Units (PNU), rather than standardized bioequivalent units. This distinguishes it from 'standardized' extracts (like certain grasses or dust mites) where the FDA has established specific reference standards for potency. Despite being non-standardized, these extracts have been a cornerstone of allergy management for decades, helping patients who suffer from seasonal allergic rhinitis (hay fever) and allergic conjunctivitis triggered by oak tree pollination.
The mechanism of Quercus Velutina Pollen varies depending on whether it is used for diagnosis or treatment. In diagnostic skin testing, a small amount of the extract is introduced into the skin (percutaneously or intradermally). If the patient has pre-existing IgE antibodies specific to Black Oak pollen, these antibodies, which are bound to mast cells in the skin, will recognize the allergen. This triggers the release of histamine and other inflammatory mediators, resulting in a 'wheal and flare' reaction (a raised bump and surrounding redness). This localized reaction confirms the patient's sensitivity to the allergen.
In allergen immunotherapy (AIT), the mechanism is much more complex and involves a fundamental shift in the immune system's response. When a patient is repeatedly exposed to increasing doses of Quercus Velutina Pollen via subcutaneous injection, the body begins to develop 'immune tolerance.' At the molecular level, several changes occur:
Unlike traditional small-molecule drugs (like ibuprofen or lisinopril), allergenic extracts like Quercus Velutina Pollen do not follow standard pharmacokinetic pathways of absorption, distribution, metabolism, and excretion. Because they are complex mixtures of proteins and glycoproteins, their 'kinetics' are better described in terms of their immunological processing.
Quercus Velutina Pollen extracts are FDA-approved for the following indications:
Off-label uses are rare, though some clinicians may use these extracts in experimental protocols for oral or sublingual immunotherapy, although these routes are not currently the standard of care for non-standardized oak extracts in the United States.
Quercus Velutina Pollen is available in several liquid formulations, typically supplied in multi-dose vials:
Concentrations are typically expressed as 1:10, 1:20, or 1:100 weight/volume (w/v), or in PNU/mL (e.g., 10,000 PNU/mL or 20,000 PNU/mL).
> Important: Only your healthcare provider can determine if Quercus Velutina Pollen is right for your specific condition. Immunotherapy must always be administered under the supervision of a physician trained in the management of anaphylaxis.
Dosage for Quercus Velutina Pollen is highly individualized and must be determined by an allergist based on the patient's sensitivity level. There is no 'one-size-fits-all' dose.
Quercus Velutina Pollen is used in children, but the starting doses may be even more conservative depending on the child's age and degree of sensitivity. Clinical studies have shown that immunotherapy is effective in children as young as 5 years old. Dosage adjustments are not strictly based on weight but rather on the clinical response and local reaction size. Immunotherapy is generally not recommended for children under the age of 5 because they may have difficulty communicating the early symptoms of a systemic reaction.
No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through the kidneys in a manner that would lead to accumulation of toxic metabolites.
No specific adjustments are necessary for hepatic impairment. However, patients with severe liver disease may have altered coagulation or protein synthesis, which should be considered by the treating physician.
Older adults may be at higher risk for complications if a systemic reaction occurs, particularly if they have underlying cardiovascular disease. Dosing should be approached with caution, and the physician must ensure the patient is not taking medications (like beta-blockers) that could complicate the treatment of anaphylaxis.
Quercus Velutina Pollen extract for immunotherapy is ONLY administered as a subcutaneous injection (under the skin), usually in the back of the upper arm. It must never be injected intravenously.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a maintenance dose is missed by more than a week or two, the allergist will typically reduce the dose for the next injection to ensure safety and prevent a systemic reaction.
An 'overdose' in the context of immunotherapy usually means receiving a dose higher than the patient's current tolerance level. This can lead to severe local reactions or systemic anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency of injections without medical guidance.
Most patients undergoing immunotherapy with Quercus Velutina Pollen will experience some form of local reaction at the site of the injection. These are generally not dangerous but can be uncomfortable.
> Warning: Stop taking Quercus Velutina Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.
There are no known long-term 'toxic' effects of Quercus Velutina Pollen on the organs (such as the liver or kidneys). The primary long-term consideration is the successful modification of the immune system. In rare cases, patients may develop 'serum sickness-like' reactions (joint pain, fever, and rash), though this is extremely uncommon with modern, purified extracts.
Allergenic extracts, including Quercus Velutina Pollen, can cause severe life-threatening systemic reactions, including anaphylaxis. Because of this risk:
Report any unusual symptoms, especially those occurring away from the injection site, to your healthcare provider immediately.
Quercus Velutina Pollen is a potent biological agent. It is intended for use only by physicians experienced in the diagnosis and treatment of allergies. Patients must be informed that the goal of treatment is to reduce symptoms over time, but the process carries an inherent risk of triggering the very allergic symptoms it is meant to treat.
No FDA black box warnings are specific to the 'Quercus Velutina' species alone, but ALL non-standardized allergenic extracts carry a class-wide warning regarding the risk of anaphylaxis. The warning emphasizes that systemic reactions can occur at any time during treatment, even in patients who have previously tolerated the same dose without issue. Fatalities have occurred, most commonly in patients with poorly controlled asthma.
Most patients can drive after the 30-minute observation period. However, if a patient experiences significant fatigue or receives antihistamines for a local reaction, they should avoid driving until they know how the medication affects them.
Alcohol should be avoided for several hours before and after an allergy injection. Alcohol causes vasodilation (opening of blood vessels), which can theoretically increase the speed at which the allergen is absorbed into the bloodstream, potentially increasing the risk of a systemic reaction.
Immunotherapy is typically continued for 3 to 5 years. If there is no significant improvement in symptoms after 1–2 years of maintenance therapy, the physician may choose to discontinue the treatment. There is no 'withdrawal' syndrome associated with stopping Quercus Velutina Pollen, but allergy symptoms may eventually return if the immune system has not been sufficiently desensitized.
> Important: Discuss all your medical conditions, especially asthma and heart disease, with your healthcare provider before starting Quercus Velutina Pollen.
There are no absolute drug-drug contraindications that prevent the use of Quercus Velutina Pollen, but certain combinations make the treatment significantly more dangerous.
There are no well-documented interactions with herbs like St. John's Wort or Ginkgo, but patients should inform their doctor of all supplements. Some herbs have mild anticoagulant or vasodilatory effects that could theoretically influence the reaction to an injection.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any heart or blood pressure medications.
Quercus Velutina Pollen must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis include:
Oaks are highly cross-reactive. A patient sensitive to Quercus velutina (Black Oak) will almost certainly be sensitive to Quercus alba (White Oak) and Quercus rubra (Red Oak). If a patient has had a severe reaction to one species of oak extract, extreme caution must be used when testing or treating with another species.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Quercus Velutina Pollen.
Pregnancy Category C: There are no adequate and well-controlled studies of Quercus Velutina Pollen in pregnant women.
It is generally considered safe to continue Quercus Velutina Pollen immunotherapy while breastfeeding. The large protein molecules in the extract are not expected to pass into breast milk in any significant amount, and they would be digested by the infant's stomach even if they were present. However, the mother should be monitored for reactions as usual.
No dosage adjustment is required. The proteins are processed locally and by the reticuloendothelial system, not the kidneys.
No dosage adjustment is required. However, physicians should be aware of the patient's overall health and ability to tolerate emergency medications.
> Important: Special populations require individualized medical assessment and often a more cautious approach to dosing.
Quercus Velutina Pollen works through immunologic desensitization. The extract contains major allergens (proteins) from the Black Oak tree. When injected subcutaneously, these proteins are taken up by dendritic cells and presented to T-cells. This leads to the induction of T-regulatory (Treg) cells, which secrete IL-10. IL-10 induces B-cells to switch from producing IgE (the allergy antibody) to IgG4 (the blocking antibody). IgG4 prevents the allergen from cross-linking IgE on the surface of mast cells and basophils, thereby preventing the release of histamine and leukotrienes.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous administration) |
| Protein Binding | N/A (Processed by immune cells) |
| Half-life | Variable (Proteins degraded within hours to days) |
| Tmax | 15-30 minutes (for local reaction) |
| Metabolism | Proteolysis by intracellular enzymes |
| Excretion | Cellular metabolic pathways |
Quercus Velutina Pollen extract is a complex biological mixture. It contains various proteins, including the major oak allergen (often referred to as Que v 1). These proteins are soluble in aqueous solutions and are typically stabilized in 50% glycerin. The molecular weight of the primary allergens usually ranges from 10 to 70 kDa.
It is classified as a Non-Standardized Pollen Allergenic Extract. It is part of the broader category of 'Allergen Immunotherapy' products. Related medications include other tree pollen extracts (e.g., White Oak, Birch, Hickory) and standardized extracts (e.g., Short Ragweed, Timothy Grass).
Common questions about Quercus Velutina Pollen
Quercus Velutina Pollen, or Black Oak pollen extract, is primarily used for the diagnosis and treatment of seasonal allergies. In diagnostic testing, it helps doctors identify if a patient is specifically allergic to oak tree pollen through a skin prick test. For treatment, it is used in allergen immunotherapy, commonly known as allergy shots. This involves giving a patient gradually increasing amounts of the pollen extract to help their immune system build up a tolerance. Over time, this reduces the severity of symptoms like sneezing, itchy eyes, and congestion during the oak pollination season.
The most common side effects are localized reactions at the site of the injection, occurring in nearly all patients at some point. These include redness, itching, and swelling that typically resolve within a few hours. Some patients may also experience a 'large local reaction' where the swelling is several inches wide. Systemic side effects, which are less common, can include hives, nasal congestion, or a mild cough. Because the extract contains the substance the patient is allergic to, it can occasionally trigger hay fever-type symptoms shortly after the injection is administered.
It is strongly advised to avoid alcohol on the days you receive a Quercus Velutina Pollen injection. Alcohol causes your blood vessels to dilate, which could potentially speed up the absorption of the allergen into your bloodstream and increase the risk of a systemic allergic reaction. Furthermore, alcohol can mask the early symptoms of anaphylaxis or interact poorly with medications like antihistamines or epinephrine used to treat a reaction. Most allergists recommend waiting at least several hours after an injection before consuming any alcohol. Always follow the specific safety protocols provided by your allergy clinic.
The safety of starting Quercus Velutina Pollen immunotherapy during pregnancy has not been established, and it is generally avoided. Doctors typically do not start new allergy shots for pregnant patients because of the risk that a severe allergic reaction could harm the fetus. However, if a woman is already on a stable maintenance dose and becomes pregnant, her doctor may decide to continue the treatment at that same dose. The decision is based on a careful risk-benefit analysis of the mother's allergy severity versus the potential risks of treatment. You should inform your allergist immediately if you become pregnant while receiving these injections.
Allergy immunotherapy with Quercus Velutina Pollen is a long-term commitment and does not provide immediate relief like an antihistamine pill. Most patients begin to notice a significant reduction in their allergy symptoms after 6 to 12 months of consistent treatment. The first few months are spent in the 'build-up phase,' where the dose is slowly increased. Once the maintenance dose is reached, the immune system begins to change more significantly. For the best and most lasting results, the treatment is typically continued for a total of three to five years.
Yes, you can stop taking Quercus Velutina Pollen injections suddenly without experiencing a 'withdrawal' like you might with certain other medications. However, stopping the treatment before the recommended 3-to-5-year course is finished may result in your allergy symptoms returning. If you stop during the build-up phase, you will likely not have gained any lasting benefit. If you need to stop or pause your treatment due to illness or travel, you must consult your allergist. They will need to adjust your dose when you restart to ensure it is safe and doesn't trigger a reaction.
If you miss a scheduled injection of Quercus Velutina Pollen, contact your allergist's office to reschedule as soon as possible. Missing a dose can affect your 'tolerance' level, especially during the build-up phase. Depending on how long it has been since your last shot, your doctor may need to repeat the previous dose or even reduce the dose for your next injection to prevent a reaction. Do not attempt to 'double up' on doses to make up for a missed one. Consistency is key to the success and safety of allergy immunotherapy.
There is no clinical evidence to suggest that Quercus Velutina Pollen extracts cause weight gain. The extract consists of natural proteins and a small amount of preservative, which are not known to affect metabolism or appetite. If you experience weight gain while undergoing immunotherapy, it is likely due to other factors, such as the use of oral corticosteroids for asthma or other lifestyle changes. If you have concerns about weight changes, you should discuss them with your primary care physician to identify the underlying cause.
Quercus Velutina Pollen can be taken alongside most common medications, but there are important exceptions. You must tell your doctor if you are taking beta-blockers or ACE inhibitors for blood pressure or heart conditions, as these can make allergy shots more dangerous. Additionally, you should avoid taking antihistamines on the day of a diagnostic skin test, as they will block the results. However, many patients continue to take their daily allergy medications (like nasal sprays or non-sedating antihistamines) during the immunotherapy process to manage symptoms until the shots become fully effective.
The concept of 'generic' doesn't apply to allergenic extracts in the same way it does to chemical drugs. Quercus Velutina Pollen is a biological product manufactured by several different specialized laboratories, such as Greer Laboratories or HollisterStier. While different brands of Black Oak extract exist, they are all considered 'non-standardized' and are not necessarily interchangeable. Your allergist will typically stick with one manufacturer's product for your entire course of treatment to ensure the dosage remains consistent and safe.